AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9013267 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ECG
Number of subjects: 72
Study 1546723 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute infusion/glycopyrrolate pretreatment
Number of subjects: 51
Study 1546723 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute infusion/glycopyrrolate pretreatment
Number of subjects: 51
Study 1546723 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute infusion/placebo pretreatment
Number of subjects: 51
Study 1546723 — intervention group
Group type: COMPARATOR
Intervention: 30-minute infusion/placebo pretreatment
Number of subjects: 51
Study 4048086 — intervention group
Group type: EXPERIMENTAL
Intervention: Great Sensations Program (nutrition-education project)
Number of subjects: 0
Study 4048086 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 31577765 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Foot and Ankle Outcome Score (EFAOS)
Number of subjects: 227
Study 31577765 — intervention group
Group type: COMPARATOR
Intervention: Paper Foot and Ankle Outcome Score (PFAOS)
Number of subjects: 227
Study 31577765 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for methodology
Number of subjects: 227
Study 28288496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 92
Study 25953357 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IOM (3.7 μg/kg) + Active AMPH (0.1 mg/kg)
Number of subjects: 12
Study 25953357 — intervention group
Group type: COMPARATOR
Intervention: Placebo IOM + Active AMPH (0.1 mg/kg)
Number of subjects: 12
Study 23333104 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 232
Study 23333104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 21457864 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews
Number of subjects: 24
Study 21457864 — intervention group
Group type: COMPARATOR
Intervention: Utility arches
Number of subjects: 24
Study 19646081 — intervention group
Group type: EXPERIMENTAL
Intervention: Talipexole hydrochloride tablets alone
Number of subjects: 0
Study 19646081 — intervention group
Group type: EXPERIMENTAL
Intervention: Talipexole hydrochloride tablets with Madopar (co-beneldopa)
Number of subjects: 0
Study 17462549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (100 mg intramuscularly for 3 months)
Number of subjects: 29
Study 17462549 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimally conventional treatment of CKD)
Number of subjects: 29
Study 14718433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Moli1901 (10 micro mol/L)
Number of subjects: 8
Study 14718433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Moli1901
Number of subjects: 8
Study 14718433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12563960 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (200 mg orally once daily, 200/100 mg twice daily)
Number of subjects: 90
Study 12563960 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (250 mg orally twice daily)
Number of subjects: 90
Study 8810062 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated intake (same-day appointment)
Number of subjects: 78
Study 8810062 — intervention group
Group type: COMPARATOR
Intervention: Standard intake (1- to 7-day delay)
Number of subjects: 78
Study 1433666 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis
Number of subjects: 41
Study 1433666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimpregnated prosthesis
Number of subjects: 41
Study 1433666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular group (patients with vascular disease)
Number of subjects: 41
Study 1433666 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy (control group)
Number of subjects: 41
Study 6376951 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed protein‐glucose (PHP‐G) diet
Number of subjects: 16
Study 6376951 — intervention group
Group type: COMPARATOR
Intervention: Crystalline amino acid‐glucose (CAA‐G) diet
Number of subjects: 16
Study 31251694 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 31251694 — intervention group
Group type: COMPARATOR
Intervention: Interval cytoreductive surgery (CRS)
Number of subjects: 0
Study 29439612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on risk factors (largest LN metastasis diameter, number of metastatic LNs, extent of extranodal invasion)
Number of subjects: 1788
Study 29439612 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set for nomogram development
Number of subjects: 1788
Study 29439612 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing and validation sets for nomogram validation
Number of subjects: 1788
Study 27553435 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 244
Study 27553435 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP)
Number of subjects: 244
Study 25048075 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 33
Study 25048075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (CYC)
Number of subjects: 33
Study 25048075 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 33
Study 22964355 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 152
Study 22964355 — intervention group
Group type: COMPARATOR
Intervention: Rest time
Number of subjects: 152
Study 20858539 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin loaded Nanostructured Lipid Carriers (ActNLCs) gel
Number of subjects: 0
Study 20858539 — intervention group
Group type: COMPARATOR
Intervention: Act plain gel
Number of subjects: 0
Study 20858539 — intervention group
Group type: EXPERIMENTAL
Intervention: ActNLCs loaded gel
Number of subjects: 0
Study 18797859 — intervention group
Group type: COMPARATOR
Intervention: Stented group (n = 58)
Number of subjects: 115
Study 18797859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstented group (n = 57)
Number of subjects: 115
Study 18797859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study 15860245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-wave velocity (PWV)
Number of subjects: 1004
Study 15860245 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-ankle PWV
Number of subjects: 1004
Study 12640369 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (OxR)
Number of subjects: 106
Study 12640369 — intervention group
Group type: COMPARATOR
Intervention: Room air (RAR)
Number of subjects: 106
Study 10657332 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg/kg/day in three doses
Number of subjects: 240
Study 10657332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 8676539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy food (HE, 2520 kcal/d, 10.5 MJ)
Number of subjects: 36
Study 8676539 — intervention group
Group type: COMPARATOR
Intervention: Regular hospital food (RHF, 1670 kcal/d, 7.0 MJ)
Number of subjects: 36
Study 1501354 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR3 group (3 mL of MVI‐Pediatric supplement, parenterally fed)
Number of subjects: 30
Study 1501354 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR2 group (2 mL, parenterally fed)
Number of subjects: 30
Study 1501354 — intervention group
Group type: COMPARATOR
Intervention: ENT group (enterally fed)
Number of subjects: 30
Study 1501354 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR3 group
Number of subjects: 30
Study 1501354 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR2 group
Number of subjects: 30
Study 1501354 — intervention group
Group type: COMPARATOR
Intervention: ENT group
Number of subjects: 30
Study 31561325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercises (aerobic + resistance exercises)
Number of subjects: 30
Study 31561325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Number of subjects: 30
Study 31561325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio tennis exercises
Number of subjects: 30
Study 30573707 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dental material (ADM)
Number of subjects: 9
Study 30573707 — intervention group
Group type: COMPARATOR
Intervention: Control (no filling of post-extraction socket)
Number of subjects: 9
Study 29111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin continued group
Number of subjects: 268
Study 29111980 — intervention group
Group type: COMPARATOR
Intervention: Metformin discontinued group
Number of subjects: 268
Study 29111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 268
Study 25877422 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-crosslinked hyaluronic acid gel (3 ml)
Number of subjects: 120
Study 25877422 — intervention group
Group type: COMPARATOR
Intervention: Control group (Foley balloon catheter only)
Number of subjects: 120
Study 25877422 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-crosslinked hyaluronic acid gel
Number of subjects: 120
Study 24037003 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shockwave treatment (three applications, once a week)
Number of subjects: 40
Study 24037003 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (ten sessions comprising ultrasound, kinesiotherapy, and guidance for home-based stretching)
Number of subjects: 40
Study 21273897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration treatment (30-min duration at 30 mins after and 1, 2, 3, and 4 days after exercise)
Number of subjects: 15
Study 21273897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration treatment
Number of subjects: 15
Study 21273897 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study 20635451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged ankle-foot orthoses (AFOs)
Number of subjects: 21
Study 20635451 — intervention group
Group type: COMPARATOR
Intervention: Typically developing (TD) children
Number of subjects: 21
Study 17961721 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 17961721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem transplants and post-transplant maintenance treatment
Number of subjects: 0
Study 17961721 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft purging
Number of subjects: 0
Study 17961721 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel drugs (bortezomib, thalidomide, lenalidomide)
Number of subjects: 0
Study 15781177 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-guided pain management training intervention
Number of subjects: 78
Study 15781177 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 78
Study 11925463 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with 80 mg of zinc as zinc oxide plus 2 mg of copper as cupric oxide
Number of subjects: 3640
Study 11925463 — intervention group
Group type: COMPARATOR
Intervention: No zinc and copper supplementation (control group)
Number of subjects: 3640
Study 9620100 — intervention group
Group type: EXPERIMENTAL
Intervention: bromfenac 25 mg
Number of subjects: 310
Study 9620100 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg
Number of subjects: 310
Study 9620100 — intervention group
Group type: COMPARATOR
Intervention: acetaminophen 325 mg
Number of subjects: 310
Study 9620100 — intervention group
Group type: EXPERIMENTAL
Intervention: bromfenac 25 mg (fed)
Number of subjects: 310
Study 9620100 — intervention group
Group type: EXPERIMENTAL
Intervention: bromfenac 25 mg (fasted)
Number of subjects: 310
Study 9620100 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg (fed)
Number of subjects: 310
Study 9620100 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg (fasted)
Number of subjects: 310
Study 9620100 — intervention group
Group type: EXPERIMENTAL
Intervention: adverse effects
Number of subjects: 310
Study 8904472 — intervention group
Group type: EXPERIMENTAL
Intervention: New catheter (Hewlett Packard HP 13975 A)
Number of subjects: 8
Study 2615927 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine, 10 mg i.v.
Number of subjects: 14
Study 2615927 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine, 25 mg i.m.
Number of subjects: 14
Study 367865 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg
Number of subjects: 16
Study 31394530 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient
Number of subjects: 459
Study 31394530 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 459
Study 31394530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both emollient and synbiotic
Number of subjects: 459
Study 31394530 — intervention group
Group type: COMPARATOR
Intervention: Neither emollient nor synbiotic (Control)
Number of subjects: 459
Study 28145158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 38
Study 28145158 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (acute dosing)
Number of subjects: 38
Study 28145158 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (chronic dosing)
Number of subjects: 38
Study 26583659 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 110
Study 26583659 — intervention group
Group type: COMPARATOR
Intervention: Conventional 4-port laparoscopic cholecystectomy (4PLC)
Number of subjects: 110
Study 23076293 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily minodronate
Number of subjects: 0
Study 23076293 — intervention group
Group type: COMPARATOR
Intervention: Weekly alendronate
Number of subjects: 0
Study 21696807 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (doxazosin-GITS) 4 mg
Number of subjects: 200
Study 21696807 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg
Number of subjects: 200
Study 19465881 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 to 20 mg/day
Number of subjects: 312
Study 19465881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 16951888 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of tobacco abstinence
Number of subjects: 201
Study 16951888 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes of tobacco abstinence
Number of subjects: 201
Study 16951888 — intervention group
Group type: COMPARATOR
Intervention: 0 minutes of tobacco abstinence
Number of subjects: 201
Study 15301577 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2mg once daily on days 15 and 16, and 4 mg once daily on days 17-28
Number of subjects: 22
Study 15301577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15301577 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 22
Study 10952418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective endothelin-1 inhibitors
Number of subjects: 0
Study 10952418 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective endothelin A receptor inhibitors
Number of subjects: 0
Study 10952418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective antagonism of endothelin receptors
Number of subjects: 0
Study 9222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 637
Study 9222947 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-intake diet compliance
Number of subjects: 637
Study 9222947 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet compliance
Number of subjects: 637
Study 9222947 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise compliance
Number of subjects: 637
Study 8376442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton‐Russell skin traction
Number of subjects: 252
Study 8376442 — intervention group
Group type: COMPARATOR
Intervention: Nursed free in bed
Number of subjects: 252
Study 3527645 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.28 mg/kg bolus pre-operatively, continuous infusion of 0.0022 mg/kg/min for 48 hours, followed by oral 60 mg twice daily)
Number of subjects: 42
Study 3527645 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 42
Study 3527645 — intervention group
Group type: COMPARATOR
Intervention: Control (no diltiazem)
Number of subjects: 42
Study 31290698 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention; participants could earn R150 ($24) in abstinence-contingent incentives at each assessment.
Number of subjects: 87
Study 31290698 — intervention group
Group type: COMPARATOR
Intervention: Control group (information and monitoring); n = 47.
Number of subjects: 87
Study 29660637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine
Number of subjects: 81
Study 29660637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 26938953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injections
Number of subjects: 21
Study 24924874 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased awareness and acceptance of emotions and thoughts during treatment
Number of subjects: 144
Study 24924874 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity (poor inhibitory control)
Number of subjects: 144
Study 22278145 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 25 mg
Number of subjects: 18
Study 22278145 — intervention group
Group type: COMPARATOR
Intervention: Cicletanine 50 mg
Number of subjects: 18
Study 22278145 — intervention group
Group type: COMPARATOR
Intervention: Cicletanine 150 mg
Number of subjects: 18
Study 20578209 — intervention group
Group type: EXPERIMENTAL
Intervention: sotrastaurin 100 mg
Number of subjects: 20
Study 20578209 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine 400 mg
Number of subjects: 20
Study 20578209 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin with 400 mg cyclosporine
Number of subjects: 20
Study 20578209 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin with 100 mg cyclosporine
Number of subjects: 20
Study 18667823 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg ramosetron hydrochloride
Number of subjects: 418
Study 18667823 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg ramosetron hydrochloride
Number of subjects: 418
Study 18667823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 16208701 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus trastuzumab
Number of subjects: 169
Study 16208701 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab
Number of subjects: 169
Study 11978749 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation during infancy
Number of subjects: 401
Study 11978749 — intervention group
Group type: COMPARATOR
Intervention: Low birth weight (LBW)
Number of subjects: 401
Study 11978749 — intervention group
Group type: COMPARATOR
Intervention: Fetal anaemia (FA)
Number of subjects: 401
Study 11978749 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 401
Study 11978749 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity, placental and maternal malaria at delivery, and sex
Number of subjects: 401
Study 10219864 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct trocar insertion
Number of subjects: 1500
Study 10219864 — intervention group
Group type: COMPARATOR
Intervention: Veress needle insertion
Number of subjects: 1500
Study 7767427 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine (REP group; n = 24)
Number of subjects: 100
Study 7767427 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (AP group; n = 27)
Number of subjects: 100
Study 7767427 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic saline followed by racemic epinephrine (PRE group; n = 24)
Number of subjects: 100
Study 7767427 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic saline followed by albuterol (PA group; n = 25)
Number of subjects: 100
Study 7767427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular epinephrine
Number of subjects: 100
Study 7767427 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 100
Study 2145384 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (spinal adjustive manipulation)
Number of subjects: 18
Study 2145384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 2145384 — intervention group
Group type: COMPARATOR
Intervention: Sham group (light physical contact)
Number of subjects: 18
Study 7028411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg, intramuscular injection, three times daily for 7-10 days
Number of subjects: 111
Study 7028411 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 500 mg, intramuscular injection, three times daily for 7-10 days
Number of subjects: 111
Study 29496350 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSDM curriculum plus fact-based immunization curriculum
Number of subjects: 143
Study 29496350 — intervention group
Group type: COMPARATOR
Intervention: Fact-based immunization curriculum alone
Number of subjects: 143
Study 26872475 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-recorded vignette presenting sexual assault threat
Number of subjects: 139
Study 25216508 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) in combination with best medical treatment (BMT)
Number of subjects: 36
Study 25216508 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) only
Number of subjects: 36
Study 23046029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) combined with bleaching agents and broad-spectrum sunscreens
Number of subjects: 62
Study 23046029 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only bleaching agents and broad-spectrum sunscreens
Number of subjects: 62
Study 20120423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% combined with adapalene gel 0.1%
Number of subjects: 301